APLT - Applied Therapeutics stock plunges 30% on Phase 3 data for cardiac drug
2024-01-04 18:14:29 ET
More on Applied Therapeutics
- ARISE-HF Phase 3 Trial Likely To Disappoint Due To Multiple Red Flags
- Applied Therapeutics: Multiple Inflection Points Could Generate Substantial Value
- Applied Therapeutics: Capital Raise Forthcoming
- Applied Therapeutics stock jumps 10% on FDA, EMA submissions
- Seeking Alpha’s Quant Rating on Applied Therapeutics
For further details see:
Applied Therapeutics stock plunges 30% on Phase 3 data for cardiac drug